In a preclinical study, UC Davis Comprehensive Cancer Center scientists developed a highly targeted gene therapy that could revolutionize treatment for cancers linked to a common herpesvirus, with ...

Gene Therapy for Type 2 Diabetes Enters Human Trial ...

D Molecular Therapeutics (NASDAQ:FDMT) executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage devel ...

The agency's decision is based on results from a clinical trial in which the treatment improved hearing in 80 percent of the pediatric participants. However, Deaf community advocates worry about the p ...

Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA ...

Detalimogene voraplasmid lead to numerous durable complete responses with favorable safety ...

A breakthrough FDA-approved treatment is changing how genetic deafness is treated.

Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial, securing a ...

The FDA has approved Otarmeni, the first-ever gene therapy for genetic hearing loss caused by the OTOF gene, for both pediatric and adult patients after positive results.

Kelly Anne is a deputy editor at Forbes Advisor overseeing the development of various initiatives, including newsletters, social media, and new content verticals. Previously, she worked as a senior ...

Researchers say a gene therapy allowed deaf children and adults as old as 32 to hear for the first time. The benefits have persisted for more than two years for some patients.